Chicago, IL, United States of America

Guifa Xi

This inventor holds 1 USPTO granted patent. Top assignee: Northwestern University. Active years: 2024.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Guifa Xi: Innovator in Cancer Treatment Methods

Introduction

Guifa Xi is a prominent inventor based in Chicago, IL, known for his groundbreaking work in cancer treatment methods. He has made significant contributions to the field of biomedical engineering, particularly through his innovative use of nanofiber stabilized growth factors.

Latest Patents

Guifa Xi holds a patent for cancer treatment methods utilizing peptide amphiphiles and glycosylated peptide amphiphiles. His patent describes compositions that include supramolecular nanostructures and methods for their use in extending the half-life of bone morphogenic proteins. These compositions promote cell differentiation, suppress proliferation, and enhance the chemosensitivity of cells, making them valuable for cancer treatment. The methods outlined in his patent also include a combinatorial approach with chemotherapeutic medications.

Career Highlights

Guifa Xi is affiliated with Northwestern University, where he continues to advance research in cancer therapies. His work has garnered attention for its potential to improve treatment outcomes for cancer patients.

Collaborations

Guifa Xi has collaborated with notable colleagues, including Samuel I. Stupp and Mark Trosper McClendon, who share his commitment to innovative research in the biomedical field.

Conclusion

Guifa Xi's contributions to cancer treatment through his patented methods highlight the importance of innovation in medical research. His work exemplifies the potential of combining advanced materials with therapeutic applications to improve patient care.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…